Valeant Pharmaceuticals International Aktie [WKN DE: A1C6JH / ISIN: CA91911K1021]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Valeant Pharmaceuticals International Inc.

27.04.18		Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting (PR Newswire)
19.04.18		Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program (PR Newswire)
19.04.18		Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program (PR Newswire)
12.04.18		Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020 (PR Newswire)
12.04.18		Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020 (PR Newswire)
11.04.18		Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery (PR Newswire)
11.04.18		Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery (PR Newswire)
11.04.18		Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes (PR Newswire)
11.04.18		Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes (PR Newswire)
09.04.18		Ortho Dermatologics: DUOBRII Shows Superiority Over Vehicle In Two Weeks (RTTNews)
09.04.18		Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology (PR Newswire)
09.04.18		Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology (PR Newswire)
06.04.18		Valeant Will Release First-Quarter 2018 Financial Results On May 8 (PR Newswire)
06.04.18		Valeant Will Release First-Quarter 2018 Financial Results On May 8 (PR Newswire)
05.04.18		Brigham families will be able to enjoy improved community spaces for a better quality of life (PR Newswire)
03.04.18		Salix Launches 'Let's Talk 2' IBS Awareness Campaign (PR Newswire)
03.04.18		Salix Launches 'Let's Talk 2' IBS Awareness Campaign (PR Newswire)
28.03.18		Microsemi's Leadership in Space Continues with Class V and Q Qualifications and QML Certification for its Radiation-Tolerant Eight-Channel Source Driver, Now in Production (PR Newswire)
26.03.18		Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes (PR Newswire)
26.03.18		Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes (PR Newswire)
19.03.18		ShangPharma Innovation Expands Incubator to Drive Life Science Innovation in Bay Area (PR Newswire)
13.03.18		Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount (PR Newswire)
13.03.18		Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount (PR Newswire)
12.03.18		TTEC Announces Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
08.03.18		Valeant To Participate At The 2018 Barclays Global Healthcare Conference (PR Newswire)
08.03.18		Valeant To Participate At The 2018 Barclays Global Healthcare Conference (PR Newswire)
01.03.18		CEO of eFatoora Dubai and Success in the GCC (PR Newswire)
01.03.18		ZSAN Implodes, ACAD Sees Sales Growth, VRX Paints A Not So Rosy Picture (RTTNews)
28.02.18		Valeant Pharma Turns To Profit In Q4, But Revenues Miss View (RTTNews)
28.02.18		Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance (PR Newswire)
28.02.18		Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance (PR Newswire)
28.02.18		Mark Your Calendar For CDTX Data, VRX Inks Deal, VTVT On STRADFAST Watch (RTTNews)
28.02.18		Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis (PR Newswire)
28.02.18		Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis (PR Newswire)
23.02.18		Federated Investors, Inc. Files Annual Report on Form 10-K with U.S. Securities and Exchange Commission (PR Newswire)
16.02.18		Ortho Dermatologics Presents An Analysis Of SILIQ™ (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis (PR Newswire)
15.02.18		AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz (RTTNews)
14.02.18		Valeant's Ortho Dermatologics Says FDA Accepts NDA For IDP-122 Lotion (RTTNews)
14.02.18		Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment (PR Newswire)
14.02.18		Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment (PR Newswire)
09.02.18		Salix Provides Update on FDA Submission for PLENVU®* (PR Newswire)
09.02.18		Salix Provides Update on FDA Submission for PLENVU®* (PR Newswire)
06.02.18		Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28 (PR Newswire)
06.02.18		Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28 (PR Newswire)
29.01.18		Endo to Announce Fourth-Quarter 2017 Financial Results (PR Newswire)
26.01.18		Biotech Stocks Facing FDA Decision In February (RTTNews)
25.01.18		Valeant Will Reduce Debt By An Additional $200 Million (PR Newswire)
25.01.18		Valeant Will Reduce Debt By An Additional $200 Million (PR Newswire)
24.01.18		Valeant Posting Steep Loss After Goldman Sachs Initiates At Sell (RTTNews)
22.01.18		Some Branded Drugs Going Generic In 2018 (RTTNews)

Zurück | 1 | 2 | Weiter

Newssuche

Valeant Pharmaceuticals International Peer Group Nachrichten

25.04.16		Pharmakonzern Valeant findet neuen Chef bei Konkurrenz
21.03.16		Valeant setzt Vorstandschef vor die Tür

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

UNIQA Insurance-Aktie im Plus: UNIQA plant zu expandieren und Dividenden zu erhöhen

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

EZB wird wohl Leitzinsen senken - wie stark?

OMV-Aktie verliert: OMV kündigt Liefervertrag mit Gazprom

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.12.2024 06:04
Kaufwert:	EUR
	Hinzufügen Speichern